Valneva SE (VALN) Free Cash Flow (2021 - 2026)
Valneva SE (VALN) posted quarterly Free Cash Flow of -$73967.0 for Q1 2026, up 98.97% year-on-year from -$37174.3 in Q1 2025, and up 99.81% on a QoQ basis from -$39.1 million in Q4 2025.
Valneva SE (VALN) Free Cash Flow (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Free Cash Flow for 6 consecutive years, with -$73967.0 the latest figure, recorded in Q1 2026.
- Quarterly Free Cash Flow rose 98.97% year-over-year to -$73967.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.1 million (up 19.76% YoY) and the FY2025 annual result came in at -$65.2 million, up 29.31% from the prior year.
- Free Cash Flow improved to -$73967.0 in Q1 2026 per VALN's latest filing, from -$39.1 million in the prior quarter.
- Over the last five years, Free Cash Flow for VALN reached as high as $65.4 billion in Q3 2023 and fell as low as -$65.6 billion in Q2 2023.
- A 5-year average of -$42.2 million and a median of -$22.8 million in 2023 frame the typical range for Free Cash Flow.
- The largest YoY upside for Free Cash Flow was 69794.7% in 2023 against a maximum downside of 87190.81% in 2023.
- Year by year, Free Cash Flow stood at -$123.6 million in 2022, then advanced by 17.7% to -$101.7 million in 2023, then soared by 82.21% to -$18.1 million in 2024, then plunged by 115.88% to -$39.1 million in 2025, then soared by 99.81% to -$73967.0 in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$73967.0, -$39.1 million, and -$17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -73,967.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73,967.03 |
| Mar 31, 2026 | -73,967.03 |
| Dec 31, 2025 | -39.07 Mn |
| Dec 31, 2025 | -39.07 Mn |
| Sep 30, 2025 | -17.39 Mn |
| Sep 30, 2025 | -17.39 Mn |
| Jun 30, 2025 | -1.56 Mn |
| Jun 30, 2025 | -1.56 Mn |
| Mar 31, 2025 | -7.21 Mn |
| Mar 31, 2025 | -7.21 Mn |
| Dec 31, 2024 | -18.10 Mn |
| Dec 31, 2024 | -18.10 Mn |
| Sep 30, 2024 | -4.70 Mn |
| Sep 30, 2024 | -4.70 Mn |
| Jun 30, 2024 | -42.38 Mn |
| Jun 30, 2024 | -42.38 Mn |
| Mar 31, 2024 | -27.09 Mn |
| Mar 31, 2024 | -27.09 Mn |
| Dec 31, 2023 | -101.74 Mn |
| Dec 31, 2023 | -101.74 Mn |